MODOPAR L.P. 125 (100 mg/25 mg), extended-release capsule 60 capsules
Brand page: Modopar (levodopa + benserazide) — all forms and strengths in France
Active ingredients: Benserazide hydrochloride, Benserazide, LÉVODOPA
Commercialized according to BDPMDispensing in France: Prescription only
Extended-release capsule60 capsulesorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MODOPAR L.P. 125 (100 mg/25 mg), gélule à libération prolongée
- Pharmaceutical form
- gélule à libération prolongée
- Route of administration
- orale
- Presentation description
- flacon(s) en verre brun de 60 gélule(s) avec fermeture de sécurité enfant
- Marketing authorisation holder
- ROCHE
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Aug 2017
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
64470678CIP73006663CIP133400930066638Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LÉVODOPAgélule | 100 mg · une gélule | SA |
| BENSÉRAZIDE (CHLORHYDRATE DE)gélule | 28,5 mg · une gélule | SA |
| BENSÉRAZIDE BASEgélule | 25 mg · une gélule | FT |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.